The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Smart Start for newly diagnosed DLBCL: rituximab/lenalidomide/ibrutinib
The Smart Start trial (NCT02636322) is looking at the combination of rituximab, lenalidomide and ibrutinib alone, prior to combination with chemotherapy, in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Here, Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the results presented by Jason Westin at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
